13G Filing: RA Capital Management and Sunesis Pharmaceuticals Inc (SNSS)

Sunesis Pharmaceuticals Inc (NASDAQ:SNSS): Peter Kolchinsky’s RA Capital Management filed an amended 13D.

You can check out RA Capital Management’s latest holdings and filings here.

Please follow RA Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about RA Capital Management or update its stock holdings.

Peter Kolchinsky
Peter Kolchinsky
RA Capital Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
RA Capital Management 0 3,596,840 0 3,596,840 3,596,840 10.4%
Peter Kolchinsky 0 3,596,840 0 3,596,840 3,596,840 10.4%
Peter Kolchinsky
Peter Kolchinsky
RA Capital Management

Page 1 of 8 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of
1934

(Amendment No. ___)*

SUNESIS PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

867328700

(CUSIP Number)

October 25, 2017

(Date of Event Which Requires Filing of
this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

[ X ] Rule 13d-1(b)
[    ] Rule 13d-1(c)
[   ] Rule 13d-1(d)

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)